Want to see HIT full AI Analyst Report?
Top Page
Health In Tech, Inc. Class A
(NASDAQ:HIT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.99
▼(-6.60% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by deteriorating TTM profitability and negative operating/free cash flow, despite a very low-debt balance sheet. Technicals further weaken the setup with the stock below key moving averages and negative MACD. The earnings call provides some support through reaffirmed guidance and sizable contracted/pipeline revenue, but near-term execution, working-capital, and liquidity pressures remain evident.
Positive Factors
Very Low Leverage
Minimal leverage gives Health In Tech financial flexibility to fund product development and distribution growth without substantial interest obligations. The stronger equity base also provides resilience if operating losses persist during the scaling phase.
Negative Factors
Profitability Deterioration
The shift from prior profitability to losses indicates that current growth investments and operating costs are exceeding revenue contribution. Sustained negative margins could limit internally funded expansion and require stronger execution before the model demonstrates operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Minimal leverage gives Health In Tech financial flexibility to fund product development and distribution growth without substantial interest obligations. The stronger equity base also provides resilience if operating losses persist during the scaling phase.
Read all positive factors
Health In Tech, Inc. Class A (HIT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$66.85M
Dividend YieldN/A
Average Volume (3M)86.29K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth22.98%
EPS Growth-362.10%
CountryUS
Employees89
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.07
Shares Outstanding53,834,660
10 Day Avg. Volume58,983
30 Day Avg. Volume86,289
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)5.19
Price to Sales (P/S)2.66
P/FCF Ratio-1.58K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside230.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$46.83M
Health In Tech, Inc. Class A Business Overview & Revenue Model
Company Description
Health In Tech, Inc. operates as a cutting-edge insurance technology provider. The company delivers a range of specialized insurance solutions for smaller enterprises, such as value-based pricing strategies, group insurance captives, localized com...
How the Company Makes Money
Health In Tech’s revenue model is tied to providing self-funded health plan administration and related technology/services to employer clients. In general, this type of business can generate revenue from fees charged for plan administration and te...
Health In Tech, Inc. Class A Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: the company highlighted meaningful forward-looking commercial traction — $32.3M contracted revenue, a $66.3M pipeline, $84M PPPV, nearly 20% YoY distribution growth, and major product/engineering milestones (HitRix launch, 3-year stabilization program). At the same time, near-term financials showed a Q2 GAAP revenue decline (-13.5%), negative adjusted EBITDA, widened AR days, and a reduced cash balance driven by carrier onboarding timing and increased investments. Management framed many negatives as timing or deliberate investments to scale the business, while reaffirming FY guidance. Given the sizable forward pipeline and product catalysts but clear short-term profitability and liquidity pressures, the call strikes a neutral tone between opportunity and execution/financial risk.Positive Updates
Contracted Revenue Provides Multi-quarter Visibility
Contracted revenue totaled $32.3M for the first half of 2026 (of which $17.3M was already recognized in H1), with $14.0M expected in H2 2026 and $1.0M in 2027 — demonstrating significant revenue already locked in ahead of GAAP recognition.
Negative Updates
GAAP Revenue Decline in Q2
Reported GAAP revenue for Q2 2026 was $8.1M, down 13.5% from $9.3M in Q2 2025. Management attributes this primarily to timing related to onboarding a new carrier rather than a drop in demand.
Read all updates
Q2-2026 Updates
Positive
Negative
Contracted Revenue Provides Multi-quarter Visibility
Contracted revenue totaled $32.3M for the first half of 2026 (of which $17.3M was already recognized in H1), with $14.0M expected in H2 2026 and $1.0M in 2027 — demonstrating significant revenue already locked in ahead of GAAP recognition.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 revenue guidance of $45.0M–$50.0M and highlighted $32.3M of contracted revenue for H1’26 (of which $17.3M was recognized in H1, $14.0M expected in H2 and $1.0M in 2027), a $66.3M pipeline as of July 31 (with $1.9M contracted since quarter end and $64.4M remaining at an expected conversion rate of 15%–40%), and platform placed plan value (PPPV) of $84M as of June 30; Q2 GAAP revenue was $8.1M (down 13.5% y/y from $9.3M) with H1 revenue of $16.8M, Q2 adjusted EBITDA of -$1.3M (H1 -$2.6M), Q2 net loss $2.5M (H1 net loss $1.4M), operating expenses of $7.3M (sales & marketing $2.2M, G&A $4.3M, R&D $0.9M with $0.8M capitalized), AR days of 55 in H1 (vs. 20 in H1’25), cash $6.5M and working capital $11.8M, total assets $29.6M and equity $19.4M, and a distribution network of 933 partners (up 19.9% y/y); management expects gross margins in the ~45%–50% range, plans to launch HitRix in H2 and a 3‑year rate stabilization program is live with its first employer, and noted that adding an A‑rated carrier could materially accelerate growth (management estimated potential upside of roughly 20%–30%).Health In Tech, Inc. Class A Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.83M | 33.33M | 19.49M | 19.15M | 5.77M |
| Gross Profit | 17.70M | 20.94M | 15.44M | 16.85M | 5.44M |
| EBITDA | -4.37M | 2.57M | 1.93M | 3.76M | 205.58K |
| Net Income | -3.95M | 1.28M | 670.48K | 2.48M | 79.74K |
Balance Sheet | |||||
| Total Assets | 29.63M | 23.09M | 15.77M | 11.50M | 28.56M |
| Cash, Cash Equivalents and Short-Term Investments | 6.51M | 7.67M | 7.85M | 2.42M | 1.49M |
| Total Debt | 102.94K | 139.81K | 206.69K | 1.92M | 316.09K |
| Total Liabilities | 11.43M | 5.98M | 2.60M | 5.41M | 27.14M |
| Stockholders Equity | 19.62M | 17.11M | 13.17M | 6.09M | 1.05M |
Cash Flow | |||||
| Free Cash Flow | -4.32M | -56.11K | 1.28M | 384.52K | -436.63K |
| Operating Cash Flow | -5.11M | 3.13M | 2.18M | 1.53M | 782.75K |
| Investing Cash Flow | -2.47M | -3.13M | -836.75K | -1.94M | -1.22M |
| Financing Cash Flow | 5.95M | -187.39K | 4.09M | 1.34M | 1.88M |
Health In Tech, Inc. Class A Technical Analysis
Negative
1.06
Price Trends
1.06
Negative
1.18
Negative
1.35
Negative
Market Momentum
-0.02
Positive
41.51
Neutral
28.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIT, the sentiment is Negative. The current price of 1.06 is below the 20-day moving average (MA) of 1.07, above the 50-day MA of 1.06, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.51 is Neutral, neither overbought nor oversold. The STOCH value of 28.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIT.
Health In Tech, Inc. Class A Risk Analysis
Health In Tech, Inc. Class A disclosed 39 risk factors in its most recent earnings report. Health In Tech, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Health In Tech, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $73.58M | 15.97 | 27.45% | ― | -0.18% | ― | |
63 Neutral | $66.28M | 44.61 | 16.47% | ― | -2.23% | -28.33% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | $66.85M | -14.18 | -20.93% | ― | 22.98% | -362.10% | |
45 Neutral | $80.96M | -4.78 | -23.77% | ― | -5.72% | -60.57% |
* General Sector Average
HIT
Health In Tech, Inc. Class A
1.00
-2.24
-69.14%
WFCF
Where Food Comes From
12.50
1.00
8.70%
SSTI
SoundThinking Inc
6.17
-6.55
-51.49%
RSSS
Research Solutions
2.25
-0.70
-23.73%
Health In Tech, Inc. Class A Corporate Events
Business Operations and StrategyFinancial Disclosures
Health In Tech Highlights Q2 Results and AI Platform Growth
Positive
Aug 13, 2026
On August 13, 2026, Health In Tech, Inc. held its second-quarter 2026 earnings conference call to discuss financial and operating results for the period ended June 30, 2026, with CEO Tim Johnson and CFO Julia Qian outlining performance and platfor...
Business Operations and StrategyFinancial Disclosures
Health In Tech Reaffirms 2026 Outlook Amid Q2 Loss
Negative
Aug 13, 2026
On August 13, 2026, Health In Tech reported unaudited results for the quarter and first half ended June 30, 2026, highlighting a 19.9% year-over-year increase in distribution partners to 933 and second-quarter revenue of $8.1 million, down from $9...
Business Operations and Strategy
Health In Tech Highlights AI-Driven Self-Funded Benefits Platform
Positive
Aug 13, 2026
On August 13, 2026, Health In Tech, Inc. announced it had prepared a new investor presentation highlighting its AI‑driven platform that streamlines the design, quoting, and administration of self‑funded health plans for small and mid&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.